IP Library Granted Patent US 9,439,908
Granted Patent B2
US 9,439,908 · App. 14/353,872 · Granted Sep 13, 2016

Cross-linking composition delivered by iontophoresis, useful for the treatment of keratoconus

Inventors: Fulvio Foschini (Rome, IT); Marcello Stagni (Catania, IT); Giulio Luciani (Bagno a Ripoli, IT); Pierre Roy (Paris, FR)
Assignee: SOOFT ITALIA SPA
A61K31/525A61K9/0009A61K9/0048
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,439,908
App. No.
14/353,872
Granted
Sep 13, 2016
Kind
B2
Abstract

An improved formulation of an ophthalmic composition contains riboflavin, as cross-linking agent of corneal collagen, administered by corneal iontophoresis, able to guarantee an increased capacity of permeation of riboflavin of the corneal stroma and therefore greater therapeutic efficacy in the treatment of keratoconus.

Claims (35)

1. An ophthalmic composition useful for the treatment of keratoconus to be administered by corneal iontophoresis, wherein the cross-linking agent is riboflavin, the pH is between 6.9 and 7.2, and the value of osmolarity is between 90 and 100 mOsm/l, and the following formulation:

Riboflavin sodium phosphate

0.147

g

Sodium-EDTA

0.1

g

Tris-(hydroxymethyl)aminomethane

0.05

g

NaH 2 PO 4 •2H 2 O

0.385

g

Na 2 HPO 4 •2H 2 O

0.217

g

Distilled water

up to 100

g.

2. The ophthalmic composition according to claim 1 , wherein the pH is 7.0, and the osmolarity is 96 mOsm/l.

3. The ophthalmic composition according to claim 2 , wherein the pH value equal to 7.0 is obtained through a buffering system comprising sodium phosphate monobasic dihydrate and/or sodium phosphate dibasic dihydrate, in appropriate amounts.

4. The ophthalmic composition according to claim 1 , wherein the composition is prepared in a technical form of collirium, eye drops, gels, and in all pharmaceutical forms that enable a corneal application followed by corneal iontophoresis.

5. The ophthalmic composition according to claim 1 , wherein the ophthalmic composition is dextran free.

6. The ophthalmic composition according to claim 1 , wherein the ophthalmic composition is NaCl free.

7. An ophthalmic composition useful for the treatment of keratoconus to be administered by corneal iontophoresis, wherein the cross-linking agent is riboflavin, the pH is between 6.9 and 7.2, the value of osmolarity is between 90 and 100 mOsm/l, and the composition is NaCl free and the following formulation:

Riboflavin sodium phosphate 0.147 g

Sodium-EDTA 0.1 g

Tris-(hydroxymethyl)aminomethane 0.05 g

NaH PO 4 .2H 2 O 0.385 g

Na HPO 4 .2H 2 O 0.217 g

Distilled water up to 100 g.

8. The ophthalmic composition according to claim 7 , wherein the ophthalmic composition is dextran free.

9. The ophthalmic composition according to claim 7 , wherein the pH is 7.0, and the osmolarity is 96 mOsm/l.

10. The ophthalmic composition according to claim 7 , wherein the pH value equal to 7.0 is obtained through a buffering system comprising sodium phosphate monobasic dihydrate and/or sodium phosphate dibasic dihydrate, in appropriate amounts.

11. The ophthalmic composition according to claim 7 , wherein the composition is prepared in a technical form of collirium, eye drops, gels, and in all pharmaceutical forms that enable a corneal application followed by corneal iontophoresis.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2016
From: FOSCHINI, FULVIO
To: SOOFT ITALIA SPA
Reel/Frame 037772/0286 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2016
From: STAGNI, MARCELLO; LUCIANI, GIULIO; ROY, PIERRE
To: SOOFT ITALIA SPA
Reel/Frame 037759/0988 →
Priority Claims (1)
IT RM2011A0560 · Oct 25, 2011 · national
Continuity (1)
Related Publication 20140303173A1 · Oct 9, 2014